Regeneron Pharmaceuticals opened higher at $826.14, compared with its previous close of $818.77. In the last trading session, the stock traded between $811.63 and $828.19. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Regeneron Pharmaceuticals is now worth
$ 127.71
giving a profit of
$ 27.71 (27.71%)
Note: Past profits do not guarantee future returns.
Rating from 22 Analysts
Today's Change
$-1.50 (-0.18%)
Day High
$828.19
Day Low
$811.63
Day Open
$826.14
Prev Close
$818.77
Volume
6,18,066
1W Return
-0.27%
1M Return
8.92%
3M Return
17.31%
6M Return
19.07%
1Y Return
25.17%
Market Cap ($ Mn)
82,657
PE Ratio
19.64
PB Ratio
2.58
PEG Ratio
6.35
ROE
14.93%
ROCE
13.08%
EPS (TTM)
$12.35
1 Week
-0.27%
1 Month
8.92%
3 Months
17.31%
6 Months
19.07%
9 Months
9.05%
TD Cowen maintains Buy on Regeneron, raises price target to $980
TD Cowen maintains a Buy rating on Regeneron Pharmaceuticals. Price target raised from $960 to $980. Analyst Tyler Van Buren issued the revised rating.
9 days agoPiper Sandler raises Regeneron price target to $865, keeps overweight
Piper Sandler raised Regeneron's price target from $854 to $865. The brokerage maintained its Overweight rating on the stock. Analyst Biren Amin issued the revised price target.
10 days agoRegeneron Pharma gets EMA positive opinion on Libtayo dosing
EMA CHMP recommends extended Libtayo dosing every six weeks. Infusion time may reduce to 15-30 minutes for 350 mg dose. Decision applies to all six approved EU indications. Final European Commission approval expected in coming months.
14 days agoRegeneron's Pasatru shows zero new bone lesions in 84-week trial
Pasatru showed zero new HO lesions from weeks 56 to 84 vs 9 for placebo. Initial 56-week data demonstrated a 90% reduction in new HO lesions. Safety profile remained consistent with no deaths or discontinuations due to infection. Regulatory submissions underway in EU and Japan for broader approvals.
17 days agoRegeneron highlights promising ovarian cancer, muscle preservation trial data
Ubamatamab achieved a 73% objective response rate in recurrent LGSOC patients receiving 800 mg monotherapy. Median progression-free survival reached 11 months, surpassing historical chemotherapy benchmarks below 15% ORR. Trevogrumab combined with semaglutide preserved 50.7% of lean mass relative to semaglutide alone. Grade 1 or 2 cytokine release syndrome occurred in 90% of ubamatamab-treated patients.
27 days agoRegeneron trevogrumab prevents 70% muscle loss in Phase 2 obesity trial
Regeneron's trevogrumab preserved nearly 70% of lean mass and muscle volume in patients using semaglutide. The Phase 2 COURAGE trial showed significant lean mass preservation without enhancing total weight loss. MRI substudy indicated 71.8% muscle volume preservation for the 25 mg dose at 52 weeks. Regeneron plans a new Phase 2 trial targeting older adults with obesity and decreased muscle mass.
29 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 | |
| $174.00 | -25.13% | $23,282.77M | 39.98 |
An investment of $100 made 5 years ago in Regeneron Pharmaceuticals is now worth
$ 127.71
giving a profit of
$ 27.71 (27.71%)
Note: Past profits do not guarantee future returns.
